Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial

Background

Hypofractionated radiotherapy is an established alternative to conventional fractionation for breast cancer, but long-term evidence after mastectomy with regional nodal irradiation is scarce. We aimed to assess the long-term efficacy and adverse event profile of hypofractionated versus conventional fractionated postmastectomy radiotherapy in high-risk breast cancer.